32.68
3.98%
1.25
プレマーケット:
33.16
0.48
+1.47%
前日終値:
$31.43
開ける:
$31.62
24時間の取引高:
1.49M
Relative Volume:
1.06
時価総額:
$5.16B
収益:
$803.07M
当期純損益:
$-358.81M
株価収益率:
-13.39
EPS:
-2.44
ネットキャッシュフロー:
$-374.21M
1週間 パフォーマンス:
-0.03%
1か月 パフォーマンス:
-8.28%
6か月 パフォーマンス:
-31.66%
1年 パフォーマンス:
-35.90%
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
名前
Ionis Pharmaceuticals Inc
セクター
電話
(760) 931-9200
住所
2855 GAZELLE COURT, CARLSBAD, CA
IONS を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
32.68 | 5.16B | 803.07M | -358.81M | -374.21M | -2.44 |
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-08-02 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
2024-07-24 | アップグレード | Leerink Partners | Market Perform → Outperform |
2024-07-16 | 再開されました | Jefferies | Buy |
2024-06-14 | アップグレード | Bernstein | Underperform → Mkt Perform |
2024-04-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
2024-01-02 | アップグレード | BofA Securities | Neutral → Buy |
2023-10-23 | アップグレード | BofA Securities | Underperform → Neutral |
2023-09-29 | 開始されました | Raymond James | Strong Buy |
2023-07-31 | アップグレード | Citigroup | Neutral → Buy |
2023-06-07 | 再開されました | Piper Sandler | Overweight |
2023-05-04 | アップグレード | Citigroup | Sell → Neutral |
2023-03-21 | 開始されました | Bernstein | Underperform |
2022-12-21 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2022-09-09 | 再開されました | Morgan Stanley | Overweight |
2022-07-18 | 再開されました | Oppenheimer | Outperform |
2022-03-31 | 再開されました | Piper Sandler | Overweight |
2022-03-01 | 開始されました | Citigroup | Sell |
2022-03-01 | 開始されました | Guggenheim | Buy |
2022-02-01 | ダウングレード | BofA Securities | Buy → Underperform |
2021-12-14 | アップグレード | William Blair | Mkt Perform → Outperform |
2021-05-07 | アップグレード | UBS | Sell → Neutral |
2021-03-01 | アップグレード | Barclays | Underweight → Equal Weight |
2020-12-16 | 開始されました | UBS | Sell |
2020-12-15 | アップグレード | Cowen | Market Perform → Outperform |
2020-09-14 | 再開されました | JP Morgan | Neutral |
2020-09-02 | 開始されました | The Benchmark Company | Hold |
2020-06-01 | 再開されました | Oppenheimer | Outperform |
2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
2020-03-05 | 開始されました | Citigroup | Buy |
2019-12-13 | 開始されました | Oppenheimer | Outperform |
2019-11-13 | 開始されました | BofA/Merrill | Buy |
2019-11-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
2019-09-10 | アップグレード | Bernstein | Mkt Perform → Outperform |
2018-08-08 | 繰り返されました | Stifel | Hold |
2018-08-07 | 繰り返されました | Stifel | Hold |
2018-05-08 | ダウングレード | Evercore ISI | Outperform → In-line |
2017-10-06 | 再開されました | Goldman | Sell |
2017-08-17 | 開始されました | Evercore ISI | Outperform |
2017-08-09 | 繰り返されました | Stifel | Hold |
2017-03-10 | ダウングレード | Goldman | Neutral → Sell |
2016-12-28 | 繰り返されました | BMO Capital Markets | Outperform |
2016-12-27 | 繰り返されました | Leerink Partners | Mkt Perform |
すべてを表示
Ionis Pharmaceuticals Inc (IONS) 最新ニュース
Assenagon Asset Management S.A. Purchases 128,619 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals EVP Brian Birchler sells $176,580 in stock - MSN
Ionis Pharmaceuticals EVP Eric Swayze sells $235,678 in stock - MSN
Ionis Pharmaceuticals CEO Brett Monia sells $1.09 million in stock - MSN
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze Sells 7,154 Shares - MarketBeat
Brett P. Monia Sells 33,445 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock - MarketBeat
Ionis Pharmaceuticals CFO sells stock worth $290,989 - MSN
Ionis Pharmaceuticals exec sells $144,861 in stock By Investing.com - Investing.com Australia
Ionis Pharmaceuticals EVP sells $232,407 in stock By Investing.com - Investing.com Australia
Ionis Pharmaceuticals EVP sells $213,889 in stock - MSN
Ionis Pharmaceuticals EVP sells $232,407 in stock - MSN
Ionis Pharmaceuticals exec sells $144,861 in stock - MSN
Bennett C. Frank of Ionis Pharmaceuticals sells $222,113 in stock - MSN
Ionis Pharmaceuticals EVP sells $241,628 in stock - MSN
Ionis Pharmaceuticals EVP Brian Birchler sells $176,580 in stock By Investing.com - Investing.com Australia
Ionis Pharmaceuticals EVP Eric Swayze sells $235,678 in stock By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals CFO sells stock worth $290,989 By Investing.com - Investing.com South Africa
EVP, Chf Clinical Develop Ofcr Schneider Eugene converted options into 17,372 shares and sold $213,889 worth of shares (6,523 units at $32.79), increasing direct ownership by 23% to 58,508 units (SEC Form 4) - Quantisnow
Ionis Pharmaceuticals EVP sells $213,889 in stock By Investing.com - Investing.com UK
Ionis Pharmaceuticals EVP sells shares worth $139,855 By Investing.com - Investing.com UK
Director Yang Michael J. converted options into 1,931 shares (SEC Form 4) - Quantisnow
Ionis Pharmaceuticals (NASDAQ:IONS) Hits New 12-Month LowTime to Sell? - MarketBeat
Why Ionis Pharmaceuticals (IONS) Is the Biotech Stock with Biggest Upside Potential - Insider Monkey
Familial Lipoprotein Lipase Deficiency Market to Continue - openPR
Retinitis Pigmentosa Pipeline Assessment 2024: Therapies, Clinical Trials, and Key Companies involved by DelveInsight | Biogen, Neurotech, Ionis Pharma, Nacuity Pharma, Allegro Ophthalmics, ID Pharma - Barchart
Amyotrophic Lateral Sclerosis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Treatment Outlook | Biogen, GSK, Helixmith, Sanofi, Denali Therapeutics, Ionis Pharma, Brainstorm Cell - The Globe and Mail
Ionis Pharmaceuticals (NASDAQ:IONS) Receives Outperform Rating from Royal Bank of Canada - MarketBeat
U.S, Europe And GCC Antisense Oligonucleotide (ASO) - openPR
Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum - Marketscreener.com
Ionis enters new chapter in 2025 as commercial-stage biotech wit - GuruFocus.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by International Assets Investment Management LLC - MarketBeat
Ionis Pharma stock hits 52-week low at $33.33 amid market challenges - Investing.com Australia
US FDA approves Ionis Pharma's genetic disorder drug - AOL
Ionis Pharmaceuticals (NASDAQ:IONS) Sets New 1-Year LowShould You Sell? - MarketBeat
Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight - GlobeNewswire Inc.
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference - The Malaysian Reserve
Vanguard Group Inc's Strategic Acquisition of Ionis Pharmaceuticals Shares - GuruFocus.com
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conferenc - GuruFocus.com
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference – Company Announcement - Financial Times
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected - Benzinga
Otsuka and Ionis’ donidalorsen accepted for EMA review - The Pharma Letter
Objective long/short (IONS) Report - Stock Traders Daily
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic - Benzinga
Ionis Pharmaceuticals Initiates Phase 3 Study of Olezarsen to Treat Severe Hypertriglyceridemia - Marketscreener.com
Ionis Pharmaceuticals director Hayden buys $181k in stock By Investing.com - Investing.com Australia
Ionis Pharmaceuticals Inc (IONS) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):